Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay
18.9.2025 07:00:00 CEST | Business Wire | Press Release
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface skin cells stop performing at the same level, or “go to sleep,” causing fine lines, dehydration, and looser skin, in turn leading to skin looking and feeling less firm and more fragile.1
Skin Activator technology serves as a “wake-up call” to sleeping surface skin cells. The unique complex is powered by encapsulated CICA to help restore the skin’s moisture barrier to visibly plump and firm skin as well as microdosed mandelic acid to increase surface skin cell turnover to visibly reduce dull, uneven skin. In clinical trials, the Skin Activator Hydrating & Firming Lotion showed to be effective in improving the appearance of skin crepiness and smooth skin’s texture in one week. It was also proven to hydrate for firmer-looking skin in just four weeks. Moreover, when patients were asked about their experiences, 88% of Skin Activator Hydrating & Firming Cream users said their skin looked less crepey in 2 days, and 87% said their skin appeared more youthful after one week.2
“This launch signals a turning point in how we approach skin longevity. It’s more fundamental than wrinkles or loss of firmness, it’s about preserving surface skin health at the cellular level. As skin undergoes changes with age, it demands more precise, science-driven support. This insight fueled the development of our Skin Activator Hydrating & Firming line: a dermatologist-developed routine designed to strengthen, revitalize, and transform skin’s appearance.” ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS
|
In developing the Skin Activator Hydrating & Firming Line, Galderma partnered with a medical advisory board of leading dermatologists.
“As a dermatologist, I’m always looking for what’s next in skin science, especially when it comes to aging. That’s why I was so excited to work with Cetaphil on the Skin Activator Hydrating & Firming line. We took on one of the biggest underlying causes of visible aging: surface skin health and cell senescence. By targeting these ‘zombie cells,’ we’re helping to support skin renewal in a way that’s truly backed by science. It’s been incredibly rewarding to help bring that kind of innovation to a skincare routine patients can use all over, every day.” DR. GLYNIS ABLON*
|
A new era of skin activation, backed by science and brought to life by a cultural icon
To help bring this segment-defining line to life, Cetaphil is proud to partner with acclaimed actress, director, and advocate, Mariska Hargitay. Known for her strength, compassion, and authenticity, Hargitay represents a powerful voice in embracing beauty at every stage of life. As the face of the campaign, she will help share a message of empowerment and reinvention – giving women the tools to reawaken both their skin’s look and their aspirations. Hargitay’s partnership will span across a robust marketing effort, inclusive of PR, advertising, in-store, retailer e-commerce, and social.
Fragrance-free, non-comedogenic, and hypoallergenic, the Skin Activator Hydrating & Firming line also embraces the trending notion of “skinification,” or using facial care-inspired ingredients to address full-body skincare needs. Products within the newly launched Skin Activator Hydrating & Firming Line include:
- Cetaphil Hydrating & Firming Cream for Neck, Chest, and Face (3.4 oz.)
- Cetaphil Hydrating & Firming Cream for Body (12 oz.)
- Cetaphil Hydrating & Firming Lotion (16 oz.)
The Hydrating & Firming Line is now widely available for purchase in the United States. Galderma is working to bring this new innovation to other international markets where Cetaphil is already available. See full list of retailers here: https://www.cetaphil.com/us/where-buy. For more information, consumers can also follow Cetaphil on Instagram (@Cetaphil) and TikTok (@Cetaphil) or visit www.cetaphil.com.
About Cetaphil®
Over seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin's health every day. For more information, visit www.cetaphil.com.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermato-logical Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References and disclaimers:
- Novel Strategy for Strengthening Dermatoporotic Skin by Managing Cellular Senescence. J Drugs Dermatol. 2024 Sep 1;23(9):748-756. doi: 10.36849/JDD.8388.
- Galderma 12-week in-use study-consumer data questionnaire. Subject data on file.
* Paid Galderma Consultant; Galderma Clinical Study investigator for the Cetaphil hydrating & firming product line
View source version on businesswire.com: https://www.businesswire.com/news/home/20250917102132/en/
Contacts
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Jeffrey Smith
Head of U.S. Communications
jeffrey.smith@galderma.com
+ 1 (682) 401-8428
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press Release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press Release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press Release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press Release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom